S. 1095 119th Congress
Stop STALLING Act
- Health
- Sponsor: Sen. Klobuchar, Amy [D-MN]
- Congress.gov ↗
Latest action, Apr 10, 2025: Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.
How the House voted
The House hasn't taken a roll call on this bill in the Congresses covered.
6 cosponsors
Sponsored by Sen. Klobuchar, Amy [D-MN] (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
4 D · 2 R
- Democrat
- Republican
- Independent
Referred to: Senate: Judiciary Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
BCBSM INC
7 reports
7 reports
7 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
CROSSROADS STRATEGIES, LLC
7 reports
TEVA PHARMACEUTICALS USA, INC.
FAEGRE DRINKER BIDDLE & REATH LLP
7 reports
THE CAMPAIGN FOR SUSTAINABLE RX PRICING
MEHLMAN CONSULTING, INC.
7 reports
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)
WHITMER & WORRALL, LLC
6 reports
6 reports
The top 25 of 28 clients, by reports
| Client | Lobbying firm | Reports | Reports totaling | From | To | House |
|---|---|---|---|---|---|---|
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 7 | $28.6M | Q1 2025 | Q3 2026 | yes | |
| BCBSM INC | 7 | $206K | Q1 2025 | Q3 2026 | yes | |
| BLUE CROSS AND BLUE SHIELD ASSOCIATION | 7 | $8.8M | Q1 2025 | Q3 2026 | yes | |
| BLUE CROSS AND BLUE SHIELD OF FLORIDA INC | 7 | $810K | Q1 2025 | Q3 2026 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 7 | $8.9M | Q1 2025 | Q3 2026 | yes | |
| GUIDEWELL MUTUAL HOLDING CORPORATION | 7 | $40K | Q1 2025 | Q3 2026 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 7 | $64.5M | Q1 2025 | Q3 2026 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | CROSSROADS STRATEGIES, LLC | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| TEVA PHARMACEUTICALS USA, INC. | FAEGRE DRINKER BIDDLE & REATH LLP | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| THE CAMPAIGN FOR SUSTAINABLE RX PRICING | MEHLMAN CONSULTING, INC. | 7 | $630K | Q1 2025 | Q3 2026 | yes |
| CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) | WHITMER & WORRALL, LLC | 6 | $300K | Q1 2025 | Q2 2026 | yes |
| NOVARTIS | 6 | $13.1M | Q1 2025 | Q2 2026 | yes | |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 6 | $20.0M | Q1 2025 | Q3 2026 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 5 | $8.9M | Q1 2025 | Q3 2026 | yes | |
| BLUE CROSS AND BLUE SHIELD OF KANSAS INC | 5 | $50K | Q4 2025 | Q3 2026 | yes | |
| COUNCIL FOR INNOVATION PROMOTION (C4IP) | 5 | $450K | Q4 2025 | Q3 2026 | yes | |
| T1INTERNATIONAL USA | 4 | $0 | Q1 2025 | Q1 2026 | yes | |
| AARP | 3 | $15.6M | Q1 2025 | Q1 2026 | yes | |
| BLUECROSS BLUESHIELD OF TENNESSEE | 3 | $780K | Q1 2026 | Q3 2026 | yes | |
| KAISER FOUNDATION HEALTH PLAN INC | 3 | $1.6M | Q4 2025 | Q3 2025 | yes | |
| PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC | COVINGTON & BURLING LLP | 3 | $0 | Q1 2025 | Q2 2026 | — |
| PUBLIC CITIZEN | 3 | $306K | Q4 2025 | Q3 2026 | yes | |
| BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) | 2 | $710K | Q2 2026 | Q3 2026 | yes | |
| BLUE CROSS BLUE SHIELD OF MICHIGAN | 2 | $542K | Q1 2025 | Q3 2026 | yes | |
| AMERICAN FEDERATION OF STATE COUNTY AND MUNICIPAL EMPLOYEES | 1 | $700K | Q4 2025 | Q4 2025 | yes |